Mark J. Rosenblum, Executive VP Finance, CFO at Salarius Pharmaceuticals, Inc. (SLRX), bought 28,000 shares at $0.18 ($5K) on 2022-05-31, disclosed to the SEC on 2022-05-31.
Open-market purchase of $5k SLRX by Executive VP Finance, CFO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Clearly above the average filing.
| Filing → |
| SLRX | BUY | 2020-08-18 | $5K | — | Filing → |
| SLRX | BUY | 2020-02-20 | $2K | — | Filing → |
| SLRX | BUY | 2020-02-13 | $4K | — | Filing → |